ReviewCureus2026
Artificial Intelligence for the Detection of Small Bowel Lesions and Neoplasia: A Scoping Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) has emerged as a promising tool for improving the detection and characterization of small bowel (SB) lesions through endoscopic imaging. This scoping review mapped and synthesized the available evidence on the diagnostic performance of AI systems applied to capsule endoscopy (CE) and device-assisted enteroscopy for identifying SB lesions with potential malignant or premalignant relevance. The review was conducted according to the methodological frameworks of Arksey and O'Malley, Levac, and the Joanna Briggs Institute, and was reported in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) recommendations. Searches were performed in PubMed, Scopus, and Embase, including original studies that evaluated AI systems on SB endoscopic images or videos and reported quantitative diagnostic metrics. A total of 13 studies were included, most of them retrospective in design. The majority originated from China and Japan, and capsule endoscopy was the most commonly used imaging modality. Automated lesion detection represented the principal application of AI, often combined with diagnostic classification tasks. Most models were based on convolutional neural networks, including architectures such as ResNet50, Single Shot Multibox Detector, YOLOv5, and nnU-Net. Across studies, diagnostic performance was consistently high, with sensitivities ranging from 81.2% to 98.6%, specificities from 88.6% to 99.8%, and area under the ROC curve values close to 1.0 in several reports. AI appears to improve the detection of SB lesions and significantly reduce endoscopic reading times, particularly in capsule endoscopy. However, the current evidence remains insufficient to support the use of AI as a screening tool for SB cancer, as most available studies are retrospective and lack robust prospective multicenter validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.